PreveCeutical Medical Inc. (PREV.CN)
CAD 0.04
(0.0%)
CAD 0.04
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 181.51 Thousand CAD | -4.03% |
| 2022 | 189.13 Thousand CAD | 17.33% |
| 2021 | 161.2 Thousand CAD | -46.7% |
| 2020 | 302.45 Thousand CAD | -64.73% |
| 2019 | 857.63 Thousand CAD | -54.91% |
| 2018 | 1.9 Million CAD | -26.83% |
| 2017 | 2.59 Million CAD | 1154.77% |
| 2016 | 207.18 Thousand CAD | 159.79% |
| 2015 | 79.74 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 177.37 Thousand CAD | -4.72% |
| 2024 Q1 | 186.15 Thousand CAD | 2.56% |
| 2023 Q4 | 181.51 Thousand CAD | -13.34% |
| 2023 Q3 | 209.44 Thousand CAD | 9.04% |
| 2023 Q2 | 192.08 Thousand CAD | 15.22% |
| 2023 Q1 | 166.71 Thousand CAD | -11.85% |
| 2023 FY | 181.51 Thousand CAD | -4.03% |
| 2022 Q4 | 189.13 Thousand CAD | 23.53% |
| 2022 Q2 | 140.04 Thousand CAD | -8.99% |
| 2022 Q1 | 153.88 Thousand CAD | -4.54% |
| 2022 FY | 189.13 Thousand CAD | 17.33% |
| 2022 Q3 | 153.1 Thousand CAD | 9.32% |
| 2021 Q1 | 221.99 Thousand CAD | -26.6% |
| 2021 Q2 | 112.01 Thousand CAD | -49.54% |
| 2021 Q3 | 246.4 Thousand CAD | 119.97% |
| 2021 Q4 | 161.2 Thousand CAD | -34.58% |
| 2021 FY | 161.2 Thousand CAD | -46.7% |
| 2020 Q1 | 663.03 Thousand CAD | -22.69% |
| 2020 Q2 | 333.94 Thousand CAD | -49.63% |
| 2020 Q3 | 540.89 Thousand CAD | 61.97% |
| 2020 Q4 | 302.45 Thousand CAD | -44.08% |
| 2020 FY | 302.45 Thousand CAD | -64.73% |
| 2019 Q3 | 1.36 Million CAD | -22.13% |
| 2019 FY | 857.63 Thousand CAD | -54.91% |
| 2019 Q2 | 1.75 Million CAD | -21.44% |
| 2019 Q4 | 857.63 Thousand CAD | -37.15% |
| 2019 Q1 | 2.23 Million CAD | 17.27% |
| 2018 FY | 1.9 Million CAD | -26.83% |
| 2018 Q1 | 2.42 Million CAD | -6.59% |
| 2018 Q2 | 7.53 Million CAD | 210.12% |
| 2018 Q3 | 4.56 Million CAD | -39.33% |
| 2018 Q4 | 1.9 Million CAD | -58.37% |
| 2017 Q1 | 342.42 Thousand CAD | 29.45% |
| 2017 Q2 | 3.38 Million CAD | 887.51% |
| 2017 Q3 | 2.05 Million CAD | -39.11% |
| 2017 Q4 | 2.59 Million CAD | 26.26% |
| 2017 FY | 2.59 Million CAD | 1154.77% |
| 2016 FY | 207.18 Thousand CAD | 159.79% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q4 | 264.53 Thousand CAD | 137.63% |
| 2016 Q3 | 111.32 Thousand CAD | -9.46% |
| 2016 Q2 | 122.95 Thousand CAD | 0.0% |
| 2015 FY | 79.74 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 4.19 Million CAD | 95.672% |
| Asep Medical Holdings Inc | 25.61 Million CAD | 99.291% |
| BetterLife Pharma Inc. | 324.74 Thousand CAD | 44.107% |
| BioVaxys Technology Corp. | 113.47 Thousand CAD | -59.952% |
| ChitogenX Inc. | 534 Thousand CAD | 66.009% |
| Rapid Dose Therapeutics Corp. | 1.88 Million CAD | 90.372% |
| Defence Therapeutics Inc. | 477.74 Thousand CAD | 62.007% |
| Entheon Biomedical Corp. | 401.07 Thousand CAD | 54.744% |
| Gemina Laboratories Ltd. | 1.45 Million CAD | 87.536% |
| Glow Lifetech Corp. | 1.91 Million CAD | 90.512% |
| Lexston Life Sciences Corp. | 750.94 Thousand CAD | 75.829% |
| Pharmala Biotech Holdings Inc. | 2.41 Million CAD | 92.476% |
| Doseology Sciences Inc. | 1.1 Million CAD | 83.532% |
| MYND Life Sciences Inc. | 797.54 Thousand CAD | 77.241% |
| Nova Mentis Life Science Corp. | 31.05 Thousand CAD | -484.404% |
| PharmaTher Holdings Ltd. | 2.58 Million CAD | 92.991% |
| Telescope Innovations Corp. | 3.02 Million CAD | 93.997% |